Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancers|April 14, 2025
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future PerspectivesHo Pui Jeff Lam, Faisal Amin, Suzanne O Arulogun, et al.
Pediatric Transplantation|October 31, 2013
Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutationNiall O'Connell, Matthew Goodyer, Mary Gleeson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2021
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myelomaOlwen Westerland, Ashik Amlani, Christian Kelly-Morland, et al.
European Journal of Haematology|July 22, 2014
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphomaSarah Barton, Eliza A Hawkes, David Cunningham, et al.
Leukemia & Lymphoma|December 10, 2016
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013Mary Gleeson, Eliza A Hawkes, Clare Peckitt, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2023
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden HospitalSu Li, Bhupinder Sharma, Siraj Yusuf, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.
Pageof 2